BenBedPhar Third Industry Showcase – Rome, 20–21 February 2025
The European COST Action CA20121 “Bench to Bedside Transition for Pharmacological Regulation of NRF2 in Non-Communicable Diseases (BenBedPhar)” held its Third Industry Showcase on 20–21 February 2025 at Sapienza University of Rome, Italy, under the theme “Transcription factor NRF2: New opportunities for pharmaceutical innovations in chronic diseases” with specific title: “Unlocking NRF2 Research for Future Clinical Therapies.”
9th BenBedPhar Scientific meeting
This hybrid meeting, combining on-site and online participation, served as a strategic platform to strengthen connections between NRF2 researchers, clinicians, and biopharmaceutical companies. It aimed to accelerate the translation of basic discoveries on the NRF2 signaling pathway, a key regulator of antioxidant and cytoprotective mechanisms, into therapeutic innovations addressing cancer, metabolic, cardiovascular, and neurodegenerative diseases.
The program featured leading academic and industrial experts presenting advances in NRF2 pharmacology, including biomarkers for monitoring drug response, KEAP1/NRF2 axis modulators, and natural and synthetic NRF2 activators for clinical application. Companies such as Servatrix Biomed, GenCell-TSBiotech, and Milonex showcased their R&D pipelines, highlighting opportunities for collaborative development and commercialization.
Interactive round tables and networking sessions facilitated dialogue on preclinical and clinical endpoints, regulatory challenges, and investment strategies. By linking academic innovation with entrepreneurial initiatives, the showcase reinforced BenBedPhar’s mission to bridge scientific excellence and industrial impact.
Building on previous editions in Madrid and Athens, the Rome meeting marked a key step toward consolidating Europe’s leadership in NRF2-based drug discovery. Through sustained collaboration among scientists, clinicians, and industry stakeholders, BenBedPhar continues to pave the way for novel NRF2-targeted therapies and the economic growth of the biomedical sector.
